The bottom line is that the global number of new deaths is moving lower, with the same trend seen in all regions. The growth rate for deaths is now 1-2% across Europe and the US. The trial results for the drug Kevzara disappointed, although it did have a small positive effect on critical cases.

Read the full article on Danske Bank Research's website.